TMP195, a class IIa histone deacetylase (HDAC) inhibitor, has been reported to repolarize TAMs towards an M1-like phenotype and to synergize with PD-1 inhibitors, reducing tumor burden and metastasis in an autochthonous mouse model of breast cancer [118]. The gene discussed is HDAC9; the disease is neoplasm.